Shengjin Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shengjin Fan has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Dan Guo
Department of Hematology, the First Affiliated Hospital of Harbin Medical University
11 shared publicationsJie Liu
Department of Hematology, the First Affiliated Hospital of Harbin Medical University
11 shared publicationsYanqiu Zhao
Department of Hematology, the First Affiliated Hospital of Harbin Medical University
9 shared publicationsHuibo Li
Department of Hematology, the First Affiliated Hospital of Harbin Medical University
8 shared publicationsQi Li
Department of Hematology, the First Affiliated Hospital of Harbin Medical University
7 shared publications- Huibo Li
Department of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, China
5 shared publications
Latest Publications
- 9 October 2026
- Published by Springer Nature in Science China Life Sciences
- p. 1-20
Inflammation as a central driver in AML pathogenesis and therapy resistance
Inflammation is a prominent feature of the bone marrow microenvironment in acute myeloid leukemia and contributes to leukemic evolution, progression, and therapeutic resistance. Accumulating evidence indicates that inflammatory signals in AML arise from multiple sources, including age-associated inflammaging, mutation-driven pathways, cell-intrinsic stress programs, and external inflammatory stimuli such as infections. These signals collectively facilitate the progression from clonal hematopoiesis and other pre-leukemic states to overt leukemia and support malignant expansion. Leukemic blasts, immune effector and regulatory cells, mesenchymal stromal cells, and endothelial cells collectively establish an inflammatory niche through the production of cytokines and chemokines. This niche supports leukemic stem cell maintenance and fitness, promotes metabolic adaptation and survival, and disrupts normal hematopoiesis and immune surveillance. The inflammatory microenvironment can also compromise therapeutic efficacy by inducing drug tolerance, reinforcing protective bone marrow niches, and reshaping responses to chemotherapy, targeted therapies, immunotherapies, and transplantation-associated graft-versus-leukemia effects. Although increasing mechanistic insights have inspired strategies aimed at neutralizing inflammatory mediators, blocking downstream signaling pathways, or reprogramming the microenvironment to restore anti-leukemic immunity, such anti-inflammatory approaches remain incompletely explored in clinical practice. A deeper understanding of cell type-specific inflammatory circuits and cytokine interactions will be essential for developing rational combination therapies to overcome microenvironment-driven resistance.
- 9 October 2026
- Published by Springer Nature in Science China Life Sciences
- p. 1-20
Inflammation as a central driver in AML pathogenesis and therapy resistance
Inflammation is a prominent feature of the bone marrow microenvironment in acute myeloid leukemia and contributes to leukemic evolution, progression, and therapeutic resistance. Accumulating evidence indicates that inflammatory signals in AML arise from multiple sources, including age-associated inflammaging, mutation-driven pathways, cell-intrinsic stress programs, and external inflammatory stimuli such as infections. These signals collectively facilitate the progression from clonal hematopoiesis and other pre-leukemic states to overt leukemia and support malignant expansion. Leukemic blasts, immune effector and regulatory cells, mesenchymal stromal cells, and endothelial cells collectively establish an inflammatory niche through the production of cytokines and chemokines. This niche supports leukemic stem cell maintenance and fitness, promotes metabolic adaptation and survival, and disrupts normal hematopoiesis and immune surveillance. The inflammatory microenvironment can also compromise therapeutic efficacy by inducing drug tolerance, reinforcing protective bone marrow niches, and reshaping responses to chemotherapy, targeted therapies, immunotherapies, and transplantation-associated graft-versus-leukemia effects. Although increasing mechanistic insights have inspired strategies aimed at neutralizing inflammatory mediators, blocking downstream signaling pathways, or reprogramming the microenvironment to restore anti-leukemic immunity, such anti-inflammatory approaches remain incompletely explored in clinical practice. A deeper understanding of cell type-specific inflammatory circuits and cytokine interactions will be essential for developing rational combination therapies to overcome microenvironment-driven resistance.
- Open Access
- 18 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1961271
Dynamic white blood cell kinetics enable early risk stratification of differentiation syndrome in low- and intermediate-risk acute promyelocytic leukemia
Background: Differentiation syndrome (DS) is a potentially life-threatening complication during induction therapy for acute promyelocytic leukemia (APL). Previous studies have linked white blood cell (WBC) elevation with DS development; however, conventional WBC-based assessment mainly relies on peak values and does not adequately reflect the dynamic pattern or timing of WBC changes. We aimed to develop and internally validate an early warning model for DS based on early WBC kinetics during arsenic trioxide (ATO) induction therapy in patients with low- and intermediate-risk APL. Methods: We retrospectively analyzed 224 newly diagnosed patients with low- and intermediate-risk APL who received single-agent ATO induction therapy. Early WBC kinetics and baseline clinical parameters were analyzed using least absolute shrinkage and selection operator regression and multivariate logistic regression to construct a nomogram. Results: DS occurred in 90 patients (40.2%), with a median onset time of 8 days (interquartile range, 7–11 days). WBC doubling occurred at a median of 3 days before DS onset, whereas the WBC peak occurred at a median of 2.5 days after DS onset. Rapid WBC proliferation and increased peripheral blood promyelocyte percentage were independent risk factors, whereas prolonged WBC doubling time was associated with reduced DS risk. The nomogram showed good discrimination, with an area under the curve of 0.825 (95% confidence interval, 0.770–0.880); the corrected area under the curve remained 0.817 after bootstrap internal validation. Conclusion: Early WBC kinetic characteristics provide time-sensitive indicators for DS risk assessment. This model may assist with early DS risk stratification and monitoring in low- and intermediate-risk APL patients.
- 18 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1961271
Open AccessDynamic white blood cell kinetics enable early risk stratification of differentiation syndrome in low- and intermediate-risk acute promyelocytic leukemia
Background: Differentiation syndrome (DS) is a potentially life-threatening complication during induction therapy for acute promyelocytic leukemia (APL). Previous studies have linked white blood cell (WBC) elevation with DS development; however, conventional WBC-based assessment mainly relies on peak values and does not adequately reflect the dynamic pattern or timing of WBC changes. We aimed to develop and internally validate an early warning model for DS based on early WBC kinetics during arsenic trioxide (ATO) induction therapy in patients with low- and intermediate-risk APL. Methods: We retrospectively analyzed 224 newly diagnosed patients with low- and intermediate-risk APL who received single-agent ATO induction therapy. Early WBC kinetics and baseline clinical parameters were analyzed using least absolute shrinkage and selection operator regression and multivariate logistic regression to construct a nomogram. Results: DS occurred in 90 patients (40.2%), with a median onset time of 8 days (interquartile range, 7–11 days). WBC doubling occurred at a median of 3 days before DS onset, whereas the WBC peak occurred at a median of 2.5 days after DS onset. Rapid WBC proliferation and increased peripheral blood promyelocyte percentage were independent risk factors, whereas prolonged WBC doubling time was associated with reduced DS risk. The nomogram showed good discrimination, with an area under the curve of 0.825 (95% confidence interval, 0.770–0.880); the corrected area under the curve remained 0.817 after bootstrap internal validation. Conclusion: Early WBC kinetic characteristics provide time-sensitive indicators for DS risk assessment. This model may assist with early DS risk stratification and monitoring in low- and intermediate-risk APL patients.
- Open Access
- 6 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9)
Oncogenic Mutations and Tumor Microenvironment Alterations in Diffuse Large B‐Cell Lymphoma With Bulky Disease
Background: Bulky disease represents a clinically aggressive subset of diffuse large B‐cell lymphoma (DLBCL) associated with adverse clinical outcomes. The aim of this study was to investigate the influence of oncogenic mutations and tumor microenvironment alterations on bulky disease in DLBCL. Methods: We analyzed a cohort of 939 patients with newly diagnosed DLBCL. Using DNA ( n = 934) and RNA ( n = 524) sequencing, we compared oncogenic mutations and tumor microenvironment (TME) alterations based on tumor diameter, with cutoff values at 5.0 cm and 10.0 cm. Further stratification by mutations in key genes (CD58, STAT6, EBF1) correlated with tumor diameter revealed distinct transcriptomic and immunologic profiles. Subsequent single‐cell RNA sequencing, guided by these mutational signatures, resolved the cellular heterogeneity within the TME. Results: Integrative analysis revealed that tumor diameter correlated with increased incidence of mutations in CD58 , STAT6 , and EBF1 ; adverse genetic subtypes such as EZB‐like MYC + and TP53 Mut ; activation of oncogenic pathways (JAK/STAT, BCR, PI3K, and MYC); and an immunosuppressive tumor microenvironment. Notably, immune checkpoint molecules varied across the bulky stages, with CTLA‐4 , TIGIT , ICOS , and CD28 expression inversely correlated with tumor diameter, while CD70 and 4‐1BBL expression positively correlated. Single‐cell RNA sequencing further revealed mutation‐specific tumor microenvironment insights. CD58 ‐mutated tumor exhibited a profoundly immune‐deserted microenvironment dominated by malignant B cells with minimal immune infiltration, whereas STAT6‐ mutated tumor was associated with increased fibroblasts and CD4 + T cells, particularly regulatory T cells (Treg) and Th1‐like cells; EBF1 ‐mutated tumor was characterized by increased proportions of malignant B cells. Conclusions: Collectively, our findings highlight the biological complexity of bulky disease, identifying candidate molecular targets and providing a biological framework for future therapeutic hypothesis generation in this clinically aggressive subset of DLBCL.
- 6 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9)
Open AccessOncogenic Mutations and Tumor Microenvironment Alterations in Diffuse Large B‐Cell Lymphoma With Bulky Disease
Background: Bulky disease represents a clinically aggressive subset of diffuse large B‐cell lymphoma (DLBCL) associated with adverse clinical outcomes. The aim of this study was to investigate the influence of oncogenic mutations and tumor microenvironment alterations on bulky disease in DLBCL. Methods: We analyzed a cohort of 939 patients with newly diagnosed DLBCL. Using DNA ( n = 934) and RNA ( n = 524) sequencing, we compared oncogenic mutations and tumor microenvironment (TME) alterations based on tumor diameter, with cutoff values at 5.0 cm and 10.0 cm. Further stratification by mutations in key genes (CD58, STAT6, EBF1) correlated with tumor diameter revealed distinct transcriptomic and immunologic profiles. Subsequent single‐cell RNA sequencing, guided by these mutational signatures, resolved the cellular heterogeneity within the TME. Results: Integrative analysis revealed that tumor diameter correlated with increased incidence of mutations in CD58 , STAT6 , and EBF1 ; adverse genetic subtypes such as EZB‐like MYC + and TP53 Mut ; activation of oncogenic pathways (JAK/STAT, BCR, PI3K, and MYC); and an immunosuppressive tumor microenvironment. Notably, immune checkpoint molecules varied across the bulky stages, with CTLA‐4 , TIGIT , ICOS , and CD28 expression inversely correlated with tumor diameter, while CD70 and 4‐1BBL expression positively correlated. Single‐cell RNA sequencing further revealed mutation‐specific tumor microenvironment insights. CD58 ‐mutated tumor exhibited a profoundly immune‐deserted microenvironment dominated by malignant B cells with minimal immune infiltration, whereas STAT6‐ mutated tumor was associated with increased fibroblasts and CD4 + T cells, particularly regulatory T cells (Treg) and Th1‐like cells; EBF1 ‐mutated tumor was characterized by increased proportions of malignant B cells. Conclusions: Collectively, our findings highlight the biological complexity of bulky disease, identifying candidate molecular targets and providing a biological framework for future therapeutic hypothesis generation in this clinically aggressive subset of DLBCL.
- 30 April 2026
- Published by Elsevier in Transplant Immunology
- Vol. 96, 102391
Chidamide maintenance after allogeneic hematopoietic stem cell transplantation in mycosis fungoides: A case report
- 30 April 2026
- Published by Elsevier in Transplant Immunology
- Vol. 96, 102391
Chidamide maintenance after allogeneic hematopoietic stem cell transplantation in mycosis fungoides: A case report
- Open Access
- 28 January 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (2) , e70603
DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF
Background: Acute leukaemia is a highly aggressive malignancy with significant unmet therapeutic needs, partly due to epigenetic dysregulation. Here, we uncover deoxynucleotidyl transferase terminal‐interacting protein 1 (DNTTIP1) within the mitotic deacetylase complex (MiDAC) as a previously unrecognised epigenetic regulator crucial for leukaemic cell survival and elucidate its mechanistic and translational significance. Methods: Using cellular, biochemical, and genetic perturbations, coupled with validation in multiple in vivo leukaemia mouse models, we characterised DNTTIP1's role in acute leukaemia. An integrated multi‐omics analysis incorporating RNA‐seq, cleavage under targets and tagmentation (CUT&Tag) and assay for transposase‐accessible chromatin using sequencing (ATAC‐seq) revealed that DNTTIP1 recruits histone deacetylase 1/2 (HDAC1/2) to silence BCL2‐modifying factor (BMF) and drive leukaemogenesis, validated by chromatin immunoprecipitation quantitative PCR (ChIP‐qPCR). Drug synergy assays identify poly(ADP‐ribose) polymerase (PARP)/HDAC/BCL2 inhibitor combinatorial efficacy. Results: DNTTIP1 depletion impaired MiDAC recruitment in acute leukaemia, leading to histone H3 lysine 27 (H3K27) hyperacetylation at the BMF promoter and reactivating this effector. Upregulated BMF disrupted BCL2‐mediated survival, triggering coordinated autophagy and apoptosis. Combined HDAC1/2 and BCL2 inhibition exerts synergistic anti‐leukaemic effects, a therapeutic strategy currently under clinical evaluation. Further, PARP inhibition profoundly enhanced this synergy by impairing DNA damage repair, unveiling a novel triple‐combination strategy. Conclusions: Our work defines the DNTTIP1‒HDAC1/2‒BMF axis as a pivotal epigenetic vulnerability in acute leukaemia and provides preclinical rationale for targeting this axis. These findings offer a validated biological framework for advancing this targeted combination therapy into clinical trials. Key points: DNTTIP1 is overexpressed in acute leukaemia and associated with poor prognosis. DNTTIP1 acts as a scaffold for the MiDAC complex, recruiting HDAC1/2 to silence BMF and inhibit leukaemic cell death. Pharmacological disruption of the DNTTIP1–HDAC1/2–BMF axis impairs leukaemogenesis.
- 28 January 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (2) , e70603
Open AccessDNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF
Background: Acute leukaemia is a highly aggressive malignancy with significant unmet therapeutic needs, partly due to epigenetic dysregulation. Here, we uncover deoxynucleotidyl transferase terminal‐interacting protein 1 (DNTTIP1) within the mitotic deacetylase complex (MiDAC) as a previously unrecognised epigenetic regulator crucial for leukaemic cell survival and elucidate its mechanistic and translational significance. Methods: Using cellular, biochemical, and genetic perturbations, coupled with validation in multiple in vivo leukaemia mouse models, we characterised DNTTIP1's role in acute leukaemia. An integrated multi‐omics analysis incorporating RNA‐seq, cleavage under targets and tagmentation (CUT&Tag) and assay for transposase‐accessible chromatin using sequencing (ATAC‐seq) revealed that DNTTIP1 recruits histone deacetylase 1/2 (HDAC1/2) to silence BCL2‐modifying factor (BMF) and drive leukaemogenesis, validated by chromatin immunoprecipitation quantitative PCR (ChIP‐qPCR). Drug synergy assays identify poly(ADP‐ribose) polymerase (PARP)/HDAC/BCL2 inhibitor combinatorial efficacy. Results: DNTTIP1 depletion impaired MiDAC recruitment in acute leukaemia, leading to histone H3 lysine 27 (H3K27) hyperacetylation at the BMF promoter and reactivating this effector. Upregulated BMF disrupted BCL2‐mediated survival, triggering coordinated autophagy and apoptosis. Combined HDAC1/2 and BCL2 inhibition exerts synergistic anti‐leukaemic effects, a therapeutic strategy currently under clinical evaluation. Further, PARP inhibition profoundly enhanced this synergy by impairing DNA damage repair, unveiling a novel triple‐combination strategy. Conclusions: Our work defines the DNTTIP1‒HDAC1/2‒BMF axis as a pivotal epigenetic vulnerability in acute leukaemia and provides preclinical rationale for targeting this axis. These findings offer a validated biological framework for advancing this targeted combination therapy into clinical trials. Key points: DNTTIP1 is overexpressed in acute leukaemia and associated with poor prognosis. DNTTIP1 acts as a scaffold for the MiDAC complex, recruiting HDAC1/2 to silence BMF and inhibit leukaemic cell death. Pharmacological disruption of the DNTTIP1–HDAC1/2–BMF axis impairs leukaemogenesis.
- 19 December 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (4) , e542-e552
Clinical Characteristics, Molecular Analysis and Survival Outcomes of Patients With Extramedullary Acute Myeloid Leukemia: A Retrospective Single-Center Study
- 19 December 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (4) , e542-e552
Clinical Characteristics, Molecular Analysis and Survival Outcomes of Patients With Extramedullary Acute Myeloid Leukemia: A Retrospective Single-Center Study
- Open Access
- 18 December 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (12) , 6197-6204
Safety and efficacy of venetoclax-azacitidine combined with low-dose Idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real-world single-center experience
Despite advances in treatment, long -term survival in patients with acute myeloid leukemia (AML) remains unsatisfactory. Standard induction chemotherapy achieves complete remission (CR) rates of 60%-80% in newly diagnosed AML patients; however, relapse and chemoresistance persist as major challenges. Combined multi-target therapeutic regimens have the potential to enhance response rates and improve survival outcomes. In this propensity score matching (PSM), single-center retrospective study, we evaluated the efficacy and safety of a novel regimen-venetoclax-azacitidine combined with low-dose idarubicin and cytarabine (VAIA)།versus standard idarubicin-cytarabine (IA) therapy in newly diagnosed AML patients. Twenty-six patients treated with VAIA were compared with 52 patients treated with IA, with well-matched clinical and molecular baseline characteristics. The VAIA cohort demonstrated significantly higher CR and measurable residual disease (MRD)-negative CR rates compared to the IA cohort (84.3% vs. 61.5%, P = 0.037; and 80.8% vs. 53.8%, P = 0.026, respectively). Moreover, VAIA was associated with improved overall survival (1-year OS: 76.9% vs. 57.7%, P = 0.031) and leukemia-free survival (1-year LFS: 65.4% vs. 46.2%, P = 0.042). Subgroup analysis revealed that adverse-risk patients particularly benefited from VAIA (1-year OS: 69.2% vs. 32%, P = 0.045; 1-year LFS: 61.5% vs. 20%, P = 0.046). In both treatment groups, MRD-negative patients exhibited significantly longer survival than MRD-positive patients. The VAIA regimen also showed superior therapeutic effects in patients particularly in patients with adverse or complex cytogenetics and adverse risk, with an acceptable and manageable toxicity profile. These findings support further prospective evaluation of the VAIA regimen in AML.
- 18 December 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (12) , 6197-6204
Open AccessSafety and efficacy of venetoclax-azacitidine combined with low-dose Idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real-world single-center experience
Despite advances in treatment, long -term survival in patients with acute myeloid leukemia (AML) remains unsatisfactory. Standard induction chemotherapy achieves complete remission (CR) rates of 60%-80% in newly diagnosed AML patients; however, relapse and chemoresistance persist as major challenges. Combined multi-target therapeutic regimens have the potential to enhance response rates and improve survival outcomes. In this propensity score matching (PSM), single-center retrospective study, we evaluated the efficacy and safety of a novel regimen-venetoclax-azacitidine combined with low-dose idarubicin and cytarabine (VAIA)།versus standard idarubicin-cytarabine (IA) therapy in newly diagnosed AML patients. Twenty-six patients treated with VAIA were compared with 52 patients treated with IA, with well-matched clinical and molecular baseline characteristics. The VAIA cohort demonstrated significantly higher CR and measurable residual disease (MRD)-negative CR rates compared to the IA cohort (84.3% vs. 61.5%, P = 0.037; and 80.8% vs. 53.8%, P = 0.026, respectively). Moreover, VAIA was associated with improved overall survival (1-year OS: 76.9% vs. 57.7%, P = 0.031) and leukemia-free survival (1-year LFS: 65.4% vs. 46.2%, P = 0.042). Subgroup analysis revealed that adverse-risk patients particularly benefited from VAIA (1-year OS: 69.2% vs. 32%, P = 0.045; 1-year LFS: 61.5% vs. 20%, P = 0.046). In both treatment groups, MRD-negative patients exhibited significantly longer survival than MRD-positive patients. The VAIA regimen also showed superior therapeutic effects in patients particularly in patients with adverse or complex cytogenetics and adverse risk, with an acceptable and manageable toxicity profile. These findings support further prospective evaluation of the VAIA regimen in AML.
- Open Access
- 5 November 2025
- Published by Springer Nature in Research Square
Prevalence, risk factors, and clinical impact of posttransplant anti-HLA antibodies after HLA-mismatched allografting: A multicenter prospective study
In this prospective multicenter clinical study investigated the prevalence of, and risk factors for, posttransplant anti-human leukocyte antigen (HLA) antibodies after HLA-mismatched allogeneic stem cell transplantation (allo-SCT) and their association with clinical outcomes. A total of 314 patients were enrolled. The prevalence of class I or II anti-HLA antibodies was 66.6%, 74.2%, 58% and 52.9% at days + 7, +14, + 21, and + 28 post-SCT, respectively. A significant increase in anti-HLA class I and II antibody MFI levels was observed at all four posttransplant timepoints compared with pretransplant baselines (all P < 0.05). On the basis of the posttransplant anti-HLA antibody profile, patients were classified as follows: Cohort A (persistently positive, n = 109), Cohort B (intermittently positive, n = 166), or Cohort C (persistently negative, n = 39). Positivity for pretransplant anti-HLA antibodies could predict positivity for posttransplant anti-HLA antibodies (HR, 2.488; P = 0.006). Persistent positivity for post-SCT anti-HLA antibodies was associated with prolonged thrombocytopenia (PT), which resulted in higher nonrelapse mortality (HR, 5.004; P < 0.001) and lower overall survival (HR, 4.552; P < 0.001). Our results suggest that positivity for pre-SCT anti-HLA antibodies is a risk factor for the prevalence of post-SCT anti-HLA antibodies in HLA-mismatched recipients. Persistent positivity for posttransplant anti-HLA antibodies may contribute to PT, leading to poor survival.
- 5 November 2025
- Published by Springer Nature in Research Square
Open AccessPrevalence, risk factors, and clinical impact of posttransplant anti-HLA antibodies after HLA-mismatched allografting: A multicenter prospective study
In this prospective multicenter clinical study investigated the prevalence of, and risk factors for, posttransplant anti-human leukocyte antigen (HLA) antibodies after HLA-mismatched allogeneic stem cell transplantation (allo-SCT) and their association with clinical outcomes. A total of 314 patients were enrolled. The prevalence of class I or II anti-HLA antibodies was 66.6%, 74.2%, 58% and 52.9% at days + 7, +14, + 21, and + 28 post-SCT, respectively. A significant increase in anti-HLA class I and II antibody MFI levels was observed at all four posttransplant timepoints compared with pretransplant baselines (all P < 0.05). On the basis of the posttransplant anti-HLA antibody profile, patients were classified as follows: Cohort A (persistently positive, n = 109), Cohort B (intermittently positive, n = 166), or Cohort C (persistently negative, n = 39). Positivity for pretransplant anti-HLA antibodies could predict positivity for posttransplant anti-HLA antibodies (HR, 2.488; P = 0.006). Persistent positivity for post-SCT anti-HLA antibodies was associated with prolonged thrombocytopenia (PT), which resulted in higher nonrelapse mortality (HR, 5.004; P < 0.001) and lower overall survival (HR, 4.552; P < 0.001). Our results suggest that positivity for pre-SCT anti-HLA antibodies is a risk factor for the prevalence of post-SCT anti-HLA antibodies in HLA-mismatched recipients. Persistent positivity for posttransplant anti-HLA antibodies may contribute to PT, leading to poor survival.
- Open Access
- 20 August 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1508676
Extramedullary relapse of acute lymphoblastic leukemia treated with a CAR-T cell therapy bridge to unrelated cord blood transplantation: a case report and review of the literature
Extramedullary relapse of acute lymphoblastic leukemia (ALL) is usually associated with poor prognosis. Chimeric antigen receptor T cell (CAR-T cell) therapy followed by allogeneic hematopoietic stem cell transplantation is beneficial for relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL). Here, we report a B-ALL patient with extramedullary relapse involving several organs, including multiple lymph nodes and the breast, kidney, uterus and pancreas. After treatment with CAR-T cell therapy, positron emission tomography/computed tomography (PET/CT) revealed that she went into remission, with an almost undetectable tumor mass. She subsequently received unrelated cord blood transplantation (UCBT). Although she achieved minimal residual disease (MRD)-negative remission after UCBT for 5 months, she relapsed at the 6th month after UCBT. This patient achieved remission after subsequent interferon-α treatment for two weeks but eventually died of severe pneumonia. This case highlights the possibility of unusual relapse sites after chemotherapy and that regular biopsy of the mass is not sufficient to assess the scope and location of recurrence. PET/CT may be a useful tool to monitor the scope of extramedullary recurrence and follow-up remission. Further understanding of the pathology of extramedullary relapse is warranted to improve the management of such challenging presentations. This case suggests the efficacy of CAR-T cell therapy combined with UCBT in adult B-ALL patients with extramedullary relapse.
- 20 August 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1508676
Open AccessExtramedullary relapse of acute lymphoblastic leukemia treated with a CAR-T cell therapy bridge to unrelated cord blood transplantation: a case report and review of the literature
Extramedullary relapse of acute lymphoblastic leukemia (ALL) is usually associated with poor prognosis. Chimeric antigen receptor T cell (CAR-T cell) therapy followed by allogeneic hematopoietic stem cell transplantation is beneficial for relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL). Here, we report a B-ALL patient with extramedullary relapse involving several organs, including multiple lymph nodes and the breast, kidney, uterus and pancreas. After treatment with CAR-T cell therapy, positron emission tomography/computed tomography (PET/CT) revealed that she went into remission, with an almost undetectable tumor mass. She subsequently received unrelated cord blood transplantation (UCBT). Although she achieved minimal residual disease (MRD)-negative remission after UCBT for 5 months, she relapsed at the 6th month after UCBT. This patient achieved remission after subsequent interferon-α treatment for two weeks but eventually died of severe pneumonia. This case highlights the possibility of unusual relapse sites after chemotherapy and that regular biopsy of the mass is not sufficient to assess the scope and location of recurrence. PET/CT may be a useful tool to monitor the scope of extramedullary recurrence and follow-up remission. Further understanding of the pathology of extramedullary relapse is warranted to improve the management of such challenging presentations. This case suggests the efficacy of CAR-T cell therapy combined with UCBT in adult B-ALL patients with extramedullary relapse.